Comtan (entacapone) / Novartis, Orion Corp, Alvogen - LARVOL DELTA

Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence (clinicaltrials.gov) - P1/2 | N=96 | Not yet recruiting | Sponsor: First Affiliated Hospital of Wenzhou Medical University

New P1/2 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Targeting the SETD2-FTO-KIT pathway as a pharmacological strategy for TKI-refractory GIST. (PubMed, Acta Pharm Sin B) - P1 | "Functional experiments using FTO knockout and pharmacological inhibition (CS1 and entacapone) demonstrated that disrupting FTO activity suppresses tumor proliferation, reduces KIT expression, and restores sensitivity to imatinib both in vitro and in vivo. Collectively, our findings establish the SETD2-FTO-KIT axis as a critical mechanism driving drug resistance in GIST and reveal m6A demethylation as a key regulator of KIT mRNA stability. Targeting FTO represents a promising and actionable therapeutic strategy to overcome TKI resistance and improve outcomes for patients with advanced GIST."

Journal • Gastrointestinal Stromal Tumor • Oncology • Sarcoma • FTO • KIT • SETD2 • YTHDF2

Clinical Features and Trajectories Related to Entacapone Use in Parkinson’s Disease: insights from the French NS Park Cohort (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Comparative outcomes and healthcare costs of three device-aided pharmacotherapies for patients with advanced Parkinson's disease in Sweden: A nationwide registry-based cohort study. (PubMed, Parkinsonism Relat Disord) - "In this nationwide Swedish cohort, no statistically significant mortality difference was detected. Weighted one-year HCRU and cost estimates were lower among LC-5 users than among infusion-therapy users; however, residual confounding by disease severity, treatment selection, and other unmeasured clinical factors limits causal interpretation."

HEOR • Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Reduction-Alkylation Proteome Profiling (RAPP): A novel strategy for proteome-wide target identification. (PubMed, Anal Chim Acta) - "The RAPP method was successfully validated by verifying the interaction between BSA and heparin, recapitulating the known targets of staurosporine, oxamate, and entacapone, and identifying ATP-binding proteins...Compared with the classic TPP method, our approach enables the identification and denaturation curve fitting of 295 additional proteins that could not produce discernible melting curves in TPP, features a more simplified workflow without complicated operations or specialized equipment, and can serve as an important complementary strategy to classical modification-free ligand target identification methods. In conclusion, RAPP serves as a valuable modification-free approach for target identification and holds practical application potential in chemical biology and drug discovery research."

Journal • LDHA

Identification of Entacapone as a Novel β-Arrestin 1 Biased Antagonist of CXCR7. (PubMed, Molecules) - "Entacapone, a clinically well established COMT inhibitor, is reported for the first time as a novel biased antagonist of CXCR7, providing a new candidate molecule for drug repurposing."

Journal • CNS Disorders • Oncology • ACKR3 • ARRB1 • COMT • CXCL12

From Contested Target to Context-Aware Node: A Three-Layer Regulatory Code for Interpreting FTO's Oncogene-Tumor Suppressor Paradox in Cancer. (PubMed, Exp Cell Res) - "Multiple inhibitor classes, FB23 derivatives, proteolysis-targeting chimera (PROTAC) degraders, repurposed entacapone, and tumor-targeted nanomedicines, have entered preclinical development, yet the clinical proposition remains unresolved because no framework currently predicts directionality or matches strategy to patient...The framework reorganizes therapeutic logic, direct inhibition, indirect modulation, rational combinations, or pharmacological activation, and reframes FTO from a contested target to a context-aware one whose translation depends on direction-aware precision oncology. Because the input, processing, and output layers are frequently drawn from different experimental systems, we present this code as an interpretive and hypothesis-generating scaffold rather than a validated predictive tool: it clarifies why FTO directionality varies and defines what must be measured to anticipate it, while prospective, within-model testing is still required before..."

Journal • Review • Genetic Disorders • Obesity • Oncology • Targeted Protein Degradation • FTO • USP7 • YTHDF2

Uncovering MYOF as a novel therapeutic target in glioblastoma: mechanistic insights and drug discovery. (PubMed, Cell Death Discov) - "Notably, we identified Entacapone (ENT), a small molecule capable of targeting MYOF, which significantly impedes glioma development across experimental models...MYOF then binds to phosphorylated STAT3 and facilitates its translocation into the nucleus to regulate target gene expression. The compound ENT acts as a targeted inhibitor of this process by binding to MYOF, thereby blocking the nuclear transport of phosphorylated STAT3 and suppressing downstream signaling."

Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • IL6

Baseline dopaminergic treatment profiles of patients with advanced Parkinson’s disease prior to Levodopa-Entacapone-Carbidopa intestinal gel infusion (EAN 2026) - "Most patients also had treatment with dopamine agonists (82%; pramipexole n = 10, 2.35 ± 0.87 mg; ropinirole n = 11, 12.36 ± 5.5 mg; rotigotine patch n = 21, 8.48 ± 1.89 mg) as well as selective monoamine oxidase B inhibitors (MAO-Bi, 60%, n = 30), apomorphine pen (14%, n = 7), Amantadine (28%, n = 14) and Entacapone (70%, n = 35). The usage of dopaminergic treatments in patients with APD prior to LECIG treatment was more complex than those described in the literature. Such analyses help general neurologists identify the limits of conventional dopaminergic therapy and prompt timely referral to tertiary centers."

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Outcome of People with Parkinson´s Disease Treated with Levodopa-entacapone-carbidopa Intestinal Gel Who Failed Previous Foslevodopa/Foscarbidopa (EAN 2026) - "LECIG could be a good therapeutic option in PwP who failed fLD/fCD."

Alzheimer's Disease • CNS Disorders • Dementia • Movement Disorders • Parkinson's Disease

HOC09 EAN/MDS-ES: Infusion therapies management in advanced Parkinson’s disease (Level 2) (EAN 2026) - "Considered infusion therapies will include: continuous subcutaneous apomorphine infusion (CSAI), Levodopa/carbidopa intestinal gel infusion (LCIG), Levodopa/entacapone/carbidopa intestinal gel (LECIG) and Levodopa/carbidopa continuous subcutaneous infusion (LC‑CSCI). Clinical indications, dose titration and adjustment and adverse events management will be discussed.This session is supported with the equipment provided by:AbbVie,Nordic Infucare,STADA Specialty Care."

Metastases • CNS Disorders • Movement Disorders • Myelodysplastic Syndrome • Parkinson's Disease

Individualisation of LECIG therapy in advanced Parkinson’s disease: adapting treatment to suit patients’ lives (EAN 2026) - "Levodopa–entacapone–carbidopa intestinal gel (LECIG) is a device-aided therapy for advanced PD designed to allow flexible dosing, enabling adaptation to patients’ specific and fluctuating motor needs throughout the day. The use of multiple flow rates with the Crono® LECIG pump allows individualised medication delivery aligned with daily activities and symptom fluctuations, supporting functional independence and an active lifestyle. MS and related disorders 5"

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

SWITCH-ON: Prospective, observational study of LECIG efficacy in Parkinson’s disease patients previously treated with subcutaneous foslevodopa (EAN 2026) - P | "Background and aims: Levodopa–entacapone–carbidopa intestinal gel (LECIG) is a device-aided therapy (DAT) for advanced Parkinson's disease (PD) patients who have severe motor fluctuations and hyperkinesia/dyskinesia that persists despite treatment with optimised oral therapy combinations (Figure 1). Subcutaneous (SC) infusion of foslevodopa/foscarbidopa (Fos) is an alternative DAT option in this setting... SWITCH-ON hopes to demonstrate that intrajejunal therapy can be a feasible option after Fos, and that prior SC treatment failure is not the end of the road for patients."

Clinical • Observational data • CNS Disorders • Movement Disorders • Parkinson's Disease

Patient perceptions of the Crono® LECIG pump device in advanced Parkinson’s disease treatment – data from the ELEGANCE observational study (EAN 2026) - P | "Background and aims: Levodopa–entacapone–carbidopa intestinal gel (LECIG) infusion is a treatment option for advanced Parkinson's disease (PD). Higher device satisfaction scores in those who switched from another pump therapy, suggest the Crono® LECIG pump may address some limitations of other devices. These findings highlight the critical role of patient-reported outcomes in evaluating drug-delivery developments in PD."

Clinical • Metastases • Observational data • CNS Disorders • Movement Disorders • Parkinson's Disease

Assessing the impact of levodopa–entacapone–carbidopa intestinal gel infusion in clinical practice: patient‑centred real‑world insights (EAN 2026) - No abstract available

Clinical • Real-world • Real-world evidence • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease

Longterm efficacy and safety of levodopa/entacapone/carbidopa intestinal gel in patients with advanced Parkinson’s disease in Slovakia (EAN 2026) - No abstract available

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Entacapone Ameliorates MASLD by Inhibiting FTO Demethylase Activity. (PubMed, Drug Dev Res) - "Further, FTO expression was down-regulated by entacapone in immortalized hepatocytes. This study highlights the therapeutic potential of entacapone in the management of metabolic liver disease by targeting the FTO demethylase activity."

Journal • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

The current status of pump therapy options for advanced Parkinson's disease in Hungary (PubMed, Ideggyogy Sz) - "We review the current state of infusion (pump) therapies in Hungary, where levodopa/carbidopa intestinal gel (LCIG) has been reimbursed since 2011, continuous subcutaneous apomorphine infusion (CSAI) since2021, levodopa-entacapone-carbidopa intrajejunal infusion (LECIG) since 2022, and subcutaneous foslevodopa/foscarbidopa infusion since 2024. Based on the National Health Insurance Fund (NEAK) database, 15 392 men and 15 691 women attended reimbursed care for PD between Nov 2024 and Dec 2025. Despite broad availability, NEAK drug-traffic data (Oct 2025) indicate."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Significant correlation between patient and clinician perceptions of disease improvement with levodopa–entacapone–carbidopa intestinal gel (LECIG) in advanced Parkinson’s – data from the ELEGANCE interim analysis (WPC 2026) - P | "Reports from both clinicians and PD patients showed a significant correlation a with sustained favourable improvements in the patients’ disease following treatment with LECIG for up to one year compared with their baseline condition. Reference 1. Senek M, et al."

Clinical • Metastases • CNS Disorders • Cognitive Disorders • Movement Disorders • Parkinson's Disease

Understanding patient perceptions of treatment with levodopa–entacapone–carbidopa intestinal infusion – real world insights from the ELEGANCE study (WPC 2026) - P | "Patient satisfaction with PD therapy is an important factor that may contribute to treatment continuation. This analysis demonstrated patients were satisfied with the small, quiet and lightweight LECIG pump, and high satisfaction scores were sustained for up to two years. Reference 1."

Clinical • Real-world • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

Nationwide analysis of real-world access to and use of device-aided therapies in Parkinson's disease: insights from the French National Healthcare Data System (2015-2021). (PubMed, BMJ Neurol Open) - "They now include deep brain stimulation (DBS), levodopa-carbidopa intestinal gel (LCIG) infusion, continuous subcutaneous apomorphine infusion (CSAI), subcutaneous foslevodopa/foscarbidopa and levodopa-entacapone-carbidopa intestinal gel (LECIG) infusions. Unlike patterns observed in other countries, CSAI was the predominant DAT in France, while DBS use declined. Features of the French healthcare system, including favourable reimbursement and broad access to home nursing services, may account for this distinctive distribution."

Journal • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

Levodopa-entacapone-carbidopa intestinal gel in advanced Parkinson's disease: an analysis of interim data for Romanian patients enrolled in the ELEGANCE study. (PubMed, J Neural Transm (Vienna)) - P | "LECIG treatment for up to one year of APD patients at Romanian centers provided effective control of motor symptoms and was well tolerated, with few discontinuations. Additional benefit was observed on some NMS, in particular sleep, and in QoL."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • Sleep Disorder

Pharmacokinetics and Tolerability of Entacapone, Levodopa, and Carbidopa Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Four-Period Crossover Study Under Fasting and Fed Conditions. (PubMed, Clin Pharmacol Drug Dev) - "This study aimed to assess the pharmacokinetics, bioequivalence, and safety of a generic entacapone/levodopa/carbidopa (100/25/200 mg) tablet formulation compared to its reference listed drug (RLD, Stalevo) in healthy Chinese adults. A randomized, open-label, single-dose, four-period crossover study was conducted under fasting and fed conditions, with a 5-day washout. Concomitant high-fat food intake had a certain impact on the pharmacokinetics of each active ingredient. Adverse events (AEs) were mild, with no serious AEs reported, indicating comparable safety profiles. In conclusion, the generic formulation is bioequivalent to the RLD and demonstrates an acceptable safety profile in healthy Chinese subjects."

Clinical • Journal • PK/PD data

Comparison of blood dopamine in Parkinson's patients treated with levodopa carbidopa entacapone vs levodopa benserazide: A randomized controlled trial. (PubMed, Medicine (Baltimore)) - "In this study, no significant difference was observed in the short-term effects of LCE and LB combinations on plasma dopamine levels in patients with early-stage Parkinson's disease with unilateral involvement. Further large-scale, multicenter studies with extended follow-up are required to assess long-term clinical outcomes, including motor response duration and adverse effects."

Clinical • Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Tailoring lipid-polymer hybrid nanoparticles as smart nanocarriers for entacapone delivery for managing Parkinson's disease. (PubMed, Biomed Pharmacother) - "In vivo study using Caenorhabditis elegans as a model demonstrated survival percentages > 80% after acute exposure to the nanoformulations in concentrations up to 40 μM in both wild-type (N2) and parkinson's disease model (WLZ3) strain, and antioxidant activity for HTT@Ent (40 μM) formulation in wlz3 strain. Overall, this work shows that the encapsulation of entacapone could be an interesting alternative in solving the drug performance by improving its physicochemical properties and permeability."

Journal • CNS Disorders • Hepatocellular Cancer • Movement Disorders • Neuroblastoma • Oncology • Parkinson's Disease • Solid Tumor • Squamous Cell Carcinoma • COMT